Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
RSC Adv ; 14(27): 19174-19184, 2024 Jun 12.
Artículo en Inglés | MEDLINE | ID: mdl-38882477

RESUMEN

In this work, intelligent pH-sensitive sensors (Fe3O4/RhB@PAM) for Cr(vi) detection were successfully synthesized based on polyacrylamide (PAM) and Rhodamine B (RhB) co-modified Fe3O4 nanocomposites. The characterization results indicated that the sensors had many favorable properties, including suitable size, stable crystal structure and excellent magnetic response performance (47.59 emu g-1). In addition, the fluorescence changes during the detection process indicated that Fe3O4/RhB@PAM were "ON-OFF" intelligent sensors. When the Fe3O4/RhB@PAM sensors were placed in acidic Cr(vi) solution (pH 4), PAM acted as a pH-responsive "gatekeeper" releasing RhB, and the fluorescence intensity of released RhB was weakened by the complexation of Cr(vi). Furthermore, the fluorescence changes of the magnetic sensors were remarkably specific for Cr(vi) even in the presence of other competitive cations, and the limit of detection (LOD) for Cr(vi) was lower (0.347 µM) than the value recommended by the World Health Organization (0.96 µM). All the results presented in this study showed that the Fe3O4/RhB@PAM sensors had significant potential for Cr(vi) detection in acidic environmental samples.

2.
Open Life Sci ; 19(1): 20220802, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38737103

RESUMEN

Against the backdrop of rapid social economy and scientific and technological development, intelligent medical technology expanded based on the Internet plays a crucial role in the innovation and development of the modern medical industry. Intelligent medical technology has completely changed the fixed medical methods of the past, and it can solve the isolated defects between various unit systems, greatly improving the overall informatization level of hospitals. This article analyzed the clinical diagnosis, prevention, and treatment of neurodyspepsia syndrome (NDS) in intelligent medicine. Dyspepsia can cause palpitations, vomiting, abdominal distension, dizziness, and other symptoms so that it can cause discomfort and pain in the middle or around the epigastric region. Therefore, it is necessary to make a correct diagnosis of neurodyspepsia in order to reduce the discomfort of patients. Intelligent medical technology is of great significance in improving patients' symptoms. This study sets up a control group and an experimental group for the experiment. The control group used conventional medication technology, while the experimental group used intelligent medical technology to analyze the patient samples taken. By comparing the factors that affect patients with NDS, it was found that the physical function score of the experimental group was 6.3% lower than that of the control group. Intelligent medical technology has high diagnostic efficiency and can achieve rapid diagnosis of NDS, meeting the clinical diagnosis and prevention requirements of NDS.

3.
BMJ Open ; 13(11): e073969, 2023 11 19.
Artículo en Inglés | MEDLINE | ID: mdl-37984951

RESUMEN

INTRODUCTION: Colorectal adenoma (CRA) is a precancerous lesion for colorectal cancer. Endoscopic resection is the first-line treatment for CRA. However, CRA recurrence rate is high. This proposed study aims to determine if Chinese herbal medicine (CHM) reduces CRA recurrence. METHODS AND ANALYSIS: This project encompasses an observational, registry-based, cohort study and a nested qualitative study. The cohort study aims to include 364 postpolypectomy CRA participants at Guangdong Provincial Hospital of Chinese Medicine (GPHCM), China, with a follow-up phase of up to 1 year. In addition to routine care, these participants will receive a CHM treatment prescribed by experienced Chinese medicine (CM) clinicians. The CHM treatment encompasses CHM products and CHM formulae according to CM syndromes. The primary outcome is CRA recurrence rate at 1 year after enrolment. Secondary outcomes include characteristics of recurrent CRA, incidence of colorectal polyp (except for CRA), incidence of advanced CRA, incidence of colorectal cancer, improvement of gastrointestinal symptoms commonly seen in CRA patients, faecal occult blood test result, lipid level, fasting plasma glucose level, uric acid level, carcinoembryonic antigen, carbohydrate antigen 19-9, quality of life and safety evaluations. Logistic regression analysis will be used to explore the correlation between exposure and outcome. Qualitative interviews will be conducted among approximate 30 CRA patients from the cohort study and 10 CM practitioners in Department of Gastroenterology at GPHCM. Thematic analysis will be used to analyse qualitative data. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Human Research Ethics Committee (HREC) of GPHCM (YF2022-320-02) and registered at Royal Melbourne Institute of Technology (RMIT) HREC. The results will be disseminated in peer-reviewed journals and international academic conferences. TRIAL REGISTRATION NUMBER: ChiCTR2200065713.


Asunto(s)
Adenoma , Neoplasias Colorrectales , Medicamentos Herbarios Chinos , Humanos , Estudios de Cohortes , Medicamentos Herbarios Chinos/uso terapéutico , Calidad de Vida , Neoplasias Colorrectales/cirugía , Sistema de Registros , Adenoma/cirugía , Proteínas Adaptadoras Transductoras de Señales , Estudios Observacionales como Asunto
5.
Hum Cell ; 35(6): 1752-1765, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35930135

RESUMEN

Lymphocyte antigen 6 family member D (LY6D) was enhanced specifically in senescent cells, while its effects on pyroptosis, a programmed cell death, remains unknown. The goal of this study was to assess the role of LY6D in the mediation of pyroptosis during nonalcoholic steatohepatitis (NASH). After screening out LY6D as a specific liver fibrosis-associated gene using the GSE55747 dataset from the GEO database, we established a NASH mouse model using methionine and choline deficient-diet feeding and an in vitro model using lipopolysaccharide (LPS)-treated hepatocytes. LY6D was overexpressed in NASH livers as well as in LPS-treated hepatocytes. Silencing of LY6D inhibited NASH-associated hepatocyte pyroptosis. With the aid of bioinformatics analysis, promoter-luciferase reporter and ChIP-qPCR assays, we identified FOSL2 as an upstream transcription factor of LY6D. FOSL2, which was highly expressed in NASH, promoted LY6D transcription by binding to the promoter of LY6D. Depletion of FOSL2 significantly inhibited NASH-associated hepatocyte pyroptosis, which was significantly reversed after overexpression of LY6D. Moreover, the promotion of hepatocyte pyroptosis by the FOSL2/LY6D axis was significantly attenuated by specific inhibition of NLRP3. These findings suggesting that FOSL2/LY6D axis may be a key molecular axis and a potential target for NASH therapeutics.


Asunto(s)
Enfermedad del Hígado Graso no Alcohólico , Animales , Antígenos Ly/metabolismo , Colina/metabolismo , Proteínas Ligadas a GPI/metabolismo , Lipopolisacáridos , Hígado/metabolismo , Metionina/metabolismo , Ratones , Proteína con Dominio Pirina 3 de la Familia NLR/genética , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Enfermedad del Hígado Graso no Alcohólico/genética , Factores de Transcripción/metabolismo
6.
Biochem Genet ; 60(5): 1567-1584, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35059934

RESUMEN

Gastric cancer (GC) is a prevalent and heterogeneous malignancy in the digestive system. Increasing studies have suggested that circular RNAs are implicated in GC pathogenesis. This study aimed to explore the biological role and underlying mechanism of circRNA zinc finger protein 131 (circZNF131) in GC. The expression pattern of circZNF131, microRNA-186-5p (miR-186-5p), and 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 2 (PFKFB2) mRNA in GC tissues and cells was detected by quantitative real-time polymerase chain reaction. The stability of circZNF131 was verified using ribonuclease R assay. Functional experiments were performed by colony formation assay for cloning ability analysis, transwell assay and wounding healing assay for cell metastasis, and flow cytometry for cell apoptosis. Glycolysis metabolism was investigated by determining the levels of glucose uptake and lactate production. The protein detection of apoptosis- or glycolysis-associated markers, PFKFB2, and Ki-67 was implemented by western blot or immunohistochemistry. Dual-luciferase reporter assay was conducted to identify the interaction between miR-186-5p and circZNF131 or PFKFB2. The role of circZNF131 on tumor growth in nude mice was investigated via xenograft tumor assay. Expression analysis indicated that circZNF131 was upregulated in GC tissues and cells in a stable structure. Functional analyses showed that circZNF131 knockdown suppressed GC cell colony formation ability, migration, invasion and glycolysis metabolism, and induced cell apoptosis. Mechanically, miR-186-5p was a target of circZNF131, and miR-186-5p could bind to PFKFB2. Rescue experiments presented that miR-186-5p inhibition reversed the effects of circZNF131 knockdown on GC cell growth and glycolysis, and PFKFB2 overexpression abolished the impacts of miR-186-5p restoration on GC cell progression. Moreover, circZNF131 could positively modulate PFKFB2 expression via sponging miR-186-5p. In vivo, circZNF131 knockdown hindered GC tumor growth by regulating the miR-186-5p/PFKFB2 axis. circZNF131 could exert an oncogenic role in GC malignant development through the miR-186-5p/PFKFB2 axis, which might provide novel targets for GC treatment.


Asunto(s)
MicroARNs , Fosfofructoquinasa-2 , ARN Circular , Neoplasias Gástricas , Animales , Proliferación Celular/genética , Proteínas de Unión al ADN/genética , Regulación Neoplásica de la Expresión Génica , Glucólisis , Humanos , Ratones , Ratones Desnudos , MicroARNs/genética , Fosfofructoquinasa-2/genética , Fosfofructoquinasa-2/metabolismo , ARN Circular/genética , Neoplasias Gástricas/patología , Factores de Transcripción/genética
7.
J Gastrointest Oncol ; 13(6): 2845-2862, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36636067

RESUMEN

Background: Because stomach adenocarcinoma (STAD) has a poor prognosis, it is necessary to explore new prognostic genes to stratify patients to guide existing individualized treatments. Methods: Survival and clinical information, RNA-seq data and mutation data of STAD were acquired from The Cancer Genome Atlas (TCGA) database. Fifty-one nicotinamide adenine dinucleotide (NAD+) metabolism-related genes (NMRGs) were obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome databases. Differentially expressed NMRGs (DE-NMRGs) between STAD and normal samples were screened, and consistent clustering analysis of STAD patients was performed based on the DE-NMRGs. Survival analysis, Gene Set Enrichment Analysis (GSEA), mutation frequency analysis, immune microenvironment analysis and drug prediction were performed among different clusters. Additionally, the differentially expressed genes (DEGs) among different clusters were selected, and the intersections of DEGs and DE-NMRGs were selected as the prognostic genes. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was performed on a human gastric mucosa epithelial cell line and cancer cell line to verify the expression of the prognostic genes. Results: A total of 27 DE-NMRGs and two clusters were selected. There was a difference in survival between clusters 1 and 2. Furthermore, 18 DE-NMRGs were significantly different between clusters 1 and 2. The different Gene Ontology (GO) biological processes and KEGG pathways between clusters 1 and 2 were mainly enriched in cyclic nucleotide mediated signaling, synaptic signaling and hedgehog signaling pathway, etc. The somatic mutation frequencies were different between the two clusters, and TTN was the highest mutated gene in the patients of the clusters 1 and 2. Additionally, eight immune cells, immune score, stromal score, and estimate score were different between clusters 1 and 2. The patients in cluster 2 were sensitive to CTLA4 inhibitor treatment. Furthermore, the top five drugs (AP.24534, BX.795, Midostaurin, WO2009093927 and CCT007093) were significantly higher in cluster 1 than in cluster 2. Finally, three genes (AOX1, NNMT and PTGIS) were acquired as prognostic, and their expressions were consistent with the results of bioinformatics analysis. Conclusions: Three prognostic genes related to NAD+ metabolism in STAD were screened out, which provides a theoretical basis and reference value for future treatment and prognosis of STAD.

9.
J Cell Mol Med ; 24(10): 5446-5453, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32227625

RESUMEN

No study has evaluated the impact of different iodinated contrast media on coronary contrast enhancement, using an injection protocol according to body surface area (BSA). Thus, the present study aimed to examine the usefulness and safety of personalized application of different iodine concentrations of contrast media in coronary computed tomographic (CT) angiography with a 2nd dual-source CT scanner in eliminating differences in coronary contrast enhancement based on a BSA-adapted injection protocol of contrast media. A total of 270 enrolled participants were randomly assigned to three groups: ioversol 320, ioversol 350 and iopromide 370 (n = 90 per group). The three groups were administered contrast media at a BSA-adjusted volume and flow rate with a fixed injection time of 15 seconds, and they subsequently received a 30-mL saline flush. All patients were scanned with a prospective electrocardiogram-gated protocol in a craniocaudal direction using a second-generation 128-slice dual-source CT system. The three iodinated contrast media used in coronary CT angiography exhibited similar diagnostic quality and safety. No significant differences were found in the contrast enhancement degrees, image quality scores, radiation doses and incidences of adverse effects among the three groups. The three contrast media used in coronary CT angiography with 320, 350 and 370 mg/mL iodine, respectively, have comparable diagnostic quality and safety. However, more large-scale, multinational, multi-centre and prospective trials are warranted.


Asunto(s)
Angiografía por Tomografía Computarizada , Medios de Contraste , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Yodo , Oligoelementos , Adulto , Anciano , Angiografía por Tomografía Computarizada/métodos , Angiografía por Tomografía Computarizada/normas , Medios de Contraste/administración & dosificación , Medios de Contraste/efectos adversos , Medios de Contraste/química , Enfermedad de la Arteria Coronaria/patología , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador/métodos , Procesamiento de Imagen Asistido por Computador/normas , Masculino , Persona de Mediana Edad
10.
Bioorg Med Chem ; 27(20): 115081, 2019 10 15.
Artículo en Inglés | MEDLINE | ID: mdl-31493989

RESUMEN

Prostate cancer (PCa) is a major cause of cancer-related male death in worldwide. To develop of potential anti-prostate cancer agents, 22 kinds of 4-Amino-2H-benzo[h]chromen-2-one analogs were designed and synthesized as potent androgen receptor (AR) antagonist through rational drug modification leading to the discovery of a series of novel antiproliferative compounds. Analogs (3, 4, 5, 7, 8, 10, 11, 12, 16, 18, 21, 23, and 24) exhibited potent antagonistic potency against AR (inhibition >50%), and exhibited potent AR binding affinities as well as displayed the higher activities than finasteride toward LNCaP cells (AR-rich) versus PC-3 cells (AR-deficient). Moreover, the docking study suggested that the most potent antagonist 23 mainly bind to AR ligand binding pocket (LBP) site through Van der Waals' force interactions. The structure-activity relationship (SAR) of these designed 4-Amino-2H-benzo[h]chromen-2-one analogs was rationally explored and discussed. Collectively, this work provides a potential lead compound for anticancer agent development related to prostate cancer therapy, and took a step forward towards the development of novel and improved AR antagonists.


Asunto(s)
Antagonistas de Receptores Androgénicos/farmacología , Antineoplásicos/farmacología , Simulación del Acoplamiento Molecular , Piperazina/farmacología , Neoplasias de la Próstata/tratamiento farmacológico , Receptores Androgénicos/metabolismo , Antagonistas de Receptores Androgénicos/síntesis química , Antagonistas de Receptores Androgénicos/química , Antineoplásicos/síntesis química , Antineoplásicos/química , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Polarización de Fluorescencia , Humanos , Masculino , Estructura Molecular , Piperazina/química , Neoplasias de la Próstata/patología , Receptores Androgénicos/genética , Relación Estructura-Actividad , Células Tumorales Cultivadas
11.
J BUON ; 21(2): 307-11, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27273938

RESUMEN

Purpose: The fifth most common cancer of the gastrointestinal system is liver cancer. It is also one of the most common cancers worldwide. The available treatment options include surgery, percutaneous ablation, and liver transplantation. Some of the latest modalities for the management of hepatocellular carcinoma (HCC) are radiofrequency ablation, trans-arterial chemoembolization, radioembolization and systemic targeted agents like sorafenib. The process of choice of a particular treatment modality in HCC depends on the tumor stage, patient performance status and liver function reserve. In the recent past with progress in research, the short-term survival of HCC has improved but recurrent disease remains a fundamental problem as the pathogenesis of HCC is a multistep and complex process. The present review is focused on recent advances in the management of HCC. This review will also provide an insight on the upcoming latest modalities including the emerging role of hepatoma-derived growth factor (HDGF) overexpression in liver fibrosis and carcinogenesis.


Asunto(s)
Carcinoma Hepatocelular/terapia , Neoplasias Hepáticas/terapia , Carcinoma Hepatocelular/mortalidad , Carcinoma Hepatocelular/patología , Humanos , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/patología , Estadificación de Neoplasias , Resultado del Tratamiento
12.
Mol Med Rep ; 11(5): 3934-40, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25572801

RESUMEN

In order to determine the protein expression of S­phase kinase­associated protein 2 (Skp2) and p27kip1, and to evaluate their possible prognostic values in malignant liver cancer, tissue samples from 50 patients and 40 controls were assessed and analyzed by immunohistochemistry and western blot analysis. Positive expression of Skp2 was observed in 35 (70.0%) of the hepatocellular carcinoma samples; however, the positive expression of p27kip1 was observed in 6 (15.0%) of the hepatocellular carcinoma samples. The expression of Skp2 was significantly negatively correlated with the expression of p27 (P<0.01). The results from Annexin V­propidium iodide staining and MTT assays indicated that interference of Skp2 significantly induced apoptosis and inhibited the proliferation of SSMC­7721 cells. In addition, the levels of endogenous p27 increased in the HepG2 and SSMC­7721 cells following transfection with siRNA specific to Skp2, suggesting that the Skp2­mediated degradation of p27kip1 was important in the proliferation of tumor cells. The present study, therefore, provided a molecular reference for the treatment of liver cancer.


Asunto(s)
Carcinogénesis/metabolismo , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patología , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/metabolismo , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patología , Proteínas Quinasas Asociadas a Fase-S/metabolismo , Apoptosis , Carcinoma Hepatocelular/genética , Línea Celular Tumoral , Proliferación Celular , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/genética , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias Hepáticas/genética , Complejo de la Endopetidasa Proteasomal/metabolismo , Transporte de Proteínas , Interferencia de ARN , Proteínas Quinasas Asociadas a Fase-S/genética , Transducción de Señal , Ubiquitina/metabolismo
13.
Opt Lett ; 33(17): 1930-2, 2008 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-18758568

RESUMEN

We demonstrate a compact, efficient Nd:YVO(4) stable-unstable hybrid slab oscillator that was partially end pumped at 880 nm. A maximum output power of 165 W at 1064 nm was obtained with an optical-to-optical efficiency from absorbed pump power to laser output of up to 60% and a slope efficiency of up to 66%. The beam propagation factors M(2) were 1.7 in the stable direction and 1.4 in the unstable direction without sidelobes.

14.
Opt Lett ; 32(10): 1262-4, 2007 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-17440554

RESUMEN

We report on a compact, efficient, and reliable monolithic Nd:YVO(4) slab oscillator-amplifier with an output power of 29.3 W in cw operation and an optical-to-optical efficiency of 24%. In electro-optically Q-switched operation, 28.8 W of average power at a repetition rate of 100 kHz with a pulse width of 15 ns was measured. The RMS stability of the pulse energy is better than 1.7%. The beam quality M(2) in both cw and pulse models was under 1.3.

15.
Opt Lett ; 32(10): 1272-4, 2007 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-17440558

RESUMEN

We demonstrate a diode-pumped electro-optical Q-switched slab laser with a high optical efficiency, high pulse energy, and short pulse width with two Nd:YLF crystals inside one resonator. The single compact slab resonator can generate a 1D top-hat beam at both the far field and the near field. With a slab-geometry-design lithium triborate (LBO) crystal, efficient critical phase-matching second-harmonic generation for a 1D top-hat beam with multiple transverse modes is achieved.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...